NCT03746288View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

July 1, 2021

Study Completion Date

December 31, 2021

Conditions
GBM
Interventions
DRUG

CAN008

CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day

Sponsors
All Listed Sponsors
lead

CANbridge Life Sciences Ltd.

INDUSTRY